GLP-1 medications have gone from niche to household name fast, and the 2026 landscape has both more options and more confusion than ever. Here's the lay of the land.
The approved options
- Semaglutide (Ozempic, Rybelsus, Wegovy)
- Tirzepatide (Mounjaro, Zepbound), dual-pathway
- Liraglutide and dulaglutide, earlier GLP-1-class options
The compounding question
Alongside the approved products sits the messy compounded market that grew during shortages. Those shortages have since resolved, and in 2026 the FDA proposed keeping semaglutide, tirzepatide, and liraglutide off the bulk-substances list permanently — so broad compounding is largely over, with only narrow exceptions. As we cover in compounded vs approved GLP-1s, there's no FDA-approved generic, and the FDA has acted against misleading marketing. The safest route remains an approved product through a licensed provider.
Bottom line
2026's GLP-1 landscape is rich but noisy. Start with the GLP-1 overview and a provider, not a too-good-to-be-true online ad.